Breaking: Biolinerx (NASDAQ:BLRX) “Buy” Rating Reiterated at Oppenheimer Today; The TP Given is $3.0

September 17, 2017 - By Dolores Ford

 Breaking: Biolinerx (NASDAQ:BLRX)

Biolinerx (NASDAQ:BLRX) Rating Reaffirmed

Biolinerx (NASDAQ:BLRX) just had their share rating of a ‘”Buy”‘ issued by research analysts at Oppenheimer, who now has a $3.0 target on the $109.32M market cap company or a 185.71 % upside potential. This key information was shown in an analyst report on Tuesday, 12 September.

Bioline RX Ltd (NASDAQ:BLRX) Ratings Coverage

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx has $7 highest and $3.0 lowest target. $3.83’s average target is 264.76% above currents $1.05 stock price. BioLineRx had 14 analyst reports since July 27, 2015 according to SRatingsIntel. Oppenheimer maintained it with “Buy” rating and $300 target in Tuesday, August 8 report. Roth Capital initiated the shares of BLRX in report on Thursday, August 3 with “Buy” rating. On Wednesday, August 9 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating by Maxim Group given on Thursday, May 18. The firm has “Buy” rating by H.C. Wainwright given on Friday, May 26. The stock has “Buy” rating by TH Capital on Monday, July 27. The stock of Bioline RX Ltd (NASDAQ:BLRX) earned “Hold” rating by Maxim Group on Friday, August 12. The rating was maintained by Oppenheimer on Tuesday, September 12 with “Buy”. On Tuesday, August 8 the stock rating was maintained by Maxim Group with “Buy”. JMP Securities maintained Bioline RX Ltd (NASDAQ:BLRX) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $3 target.

The stock increased 0.96% or $0.01 on September 15, reaching $1.05. About 125,334 shares traded. Bioline RX Ltd (NASDAQ:BLRX) has declined 6.10% since September 17, 2016 and is downtrending. It has underperformed by 22.80% the S&P500.

Wall Street await Bioline RX Ltd (NASDAQ:BLRX) to release earnings on November, 28. Analysts forecast EPS of $-0.05, up exactly $0.03 or 37.50 % from 2014’s $-0.08 EPS. After posting $-0.05 EPS for the previous quarter, Bioline RX Ltd’s analysts now forecast 0.00 % EPS growth.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. The company has market cap of $109.32 million. The Company’s clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. It currently has negative earnings.

More notable recent Bioline RX Ltd (NASDAQ:BLRX) news were published by: Seekingalpha.com which released: “BioLineRx: At Around $1, This Sleeper Biotech Stock Is A Strong Buy” on July 13, 2017, also Seekingalpha.com with their article: “BiolineRx: COMBAT Engagement” published on April 19, 2017, Nasdaq.com published: “BioLineRx Moves a Regulatory Submission for BL-8040 Trial” on August 22, 2017. More interesting news about Bioline RX Ltd (NASDAQ:BLRX) were released by: Seekingalpha.com and their article: “BioLineRx – Undervalued With Significant Pipeline, Large Pharma Collaborations …” published on February 15, 2017 as well as Seekingalpha.com‘s news article titled: “Investors Waiting In BioLineRx” with publication date: July 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.